NCT07330778RecruitingPhase 1
A Study of CDX-622 in Participants With Mild to Moderate Asthma
An Open-Label, Single-Dose Study to Assess the Safety, Pharmacodynamics, and Pharmacokinetics of CDX-622 in Adults With Mild to Moderate Asthma
Source: ClinicalTrials.gov · Last updated 2 Jul 2026
Brief summary (registry, in English)
This is a study to determine the safety, pharmacodynamics (PD), and pharmacokinetics (PK) of CDX-622 in adults with mild to moderate asthma.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- First submitted
- 26 Sept 2025
- Start date
- 1 Jun 2026
- Primary completion date
- 31 Mar 2027
- Lead sponsor
- Celldex Therapeutics
- Diseases
- Asthma
- NCT number
- NCT07330778
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 12
- From 1 Jun 2026 to the primary completion date, 31 Mar 2027
- 4 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Hospitalization for treatment of asthma in the past 12 months or required oral corticosteroids due to asthma within the past 6 months
- Immunomodulating biologic therapies within the past 3 months for non-extended half-life biologics.
- Prior receipt of TSLP or KIT inhibitors such as tezepelumab or briquilimab
- Additional protocol defined inclusion and exclusion criteria could apply.
Other illness
- Pulmonary disease other than asthma
- Systemic diseases with elevated eosinophils other than asthma
- History of needing ventilator support due to asthma
- History of smoking or vaping within the past 6 months
- Tuberculosis, hepatitis B or C virus, or HIV
Other
- Females who are pregnant or nursing
- Current nasal polyps
- Severe or uncontrolled asthma
Who the study is looking for
- Males and females, ≥ 18 years of age
- Diagnosis of mild to moderate asthma for at least 12 months
- Pre-bronchodilator forced expiratory volume in 1 second (FEV1) ≥ 70% of predicted normal
- Airway reversibility ≥ 12% and 200 mL improvement in FEV1
- Both males and females of child-bearing potential must agree to use contraception during the study and for 150 days after treatment
- Willing and able to comply with all study requirements and procedures
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (4)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Brigham and Women's Hospital Coordinator of this site? Confirm its status | Boston | United States | Recruiting |
| The University of Kansas Medical Center Coordinator of this site? Confirm its status | Kansas City | United States | Recruiting |
| University of Pittsburgh Asthma and Environmental Lung Health Institute at UPMC Coordinator of this site? Confirm its status | Pittsburgh | United States | Recruiting |
| University of California San Francisco Coordinator of this site? Confirm its status | San Francisco | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.